Consensus Criteria for Sensitive Detection of Minimal Neuroblastoma Cells in Bone Marrow, Blood and Stem Cell Preparations by Immunocytology and QRT-PCR: Recommendations by the International Neuroblastoma Risk Group Task Force

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Apr 30

PMID 19401690

Citations 48

Authors

K Beiske

S A Burchill

I Y Cheung

E Hiyama

R C Seeger

S L Cohn

A D J Pearson

K K Matthay

Affiliations

Soon will be listed here.

Abstract

Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task Force has defined standardised methods for the determination of minimal disease (MD) by immunocytology (IC) and quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) using disialoganglioside G(D2) and tyrosine hydroxylase mRNA respectively. The INRG standard operating procedures (SOPs) define methods for collecting, processing and evaluating bone marrow (BM), peripheral blood (PB) and peripheral blood stem cell harvest by IC and QRT-PCR. Sampling PB and BM is recommended at diagnosis, before and after myeloablative therapy and at the end of treatment. Peripheral blood stem cell products should be analysed at the time of harvest. Performing MD detection according to INRG SOPs will enable laboratories throughout the world to compare their results and thus facilitate quality-controlled multi-centre prospective trials to assess the clinical significance of MD and minimal residual disease in heterogeneous patient groups.

Citing Articles

Sensitive liquid biopsy monitoring correlates with outcome in the prospective international GPOH-DCOG high-risk neuroblastoma RT-qPCR validation study.

van Zogchel L, Decarolis B, van Wezel E, Zappeij-Kannegieter L, Gelineau N, Schumacher-Kuckelkorn R J Exp Clin Cancer Res. 2024; 43(1):331.

PMID: 39722049 PMC: 11670466. DOI: 10.1186/s13046-024-03261-y.

Predicting Bone Marrow Metastasis in Neuroblastoma: An Explainable Machine Learning Approach Using Contrast-Enhanced Computed Tomography Radiomics Features.

Wang H, He L, Chen X, Ding S, Xie M, Cai J Technol Cancer Res Treat. 2024; 23:15330338241290386.

PMID: 39440370 PMC: 11500234. DOI: 10.1177/15330338241290386.

Radiomics models to predict bone marrow metastasis of neuroblastoma using CT.

Chen X, Chen Q, Liu Y, Qiu Y, Lv L, Zhang Z Cancer Innov. 2024; 3(5):e135.

PMID: 38948899 PMC: 11212276. DOI: 10.1002/cai2.135.

Advances in liquid biopsy in neuroblastoma.

Zhuo Z, Lin L, Miao L, Li M, He J Fundam Res. 2024; 2(6):903-917.

PMID: 38933377 PMC: 11197818. DOI: 10.1016/j.fmre.2022.08.005.

Machine-learning radiomics to predict bone marrow metastasis of neuroblastoma using magnetic resonance imaging.

Lv L, Zhang Z, Zhang D, Chen Q, Liu Y, Qiu Y Cancer Innov. 2023; 2(5):405-415.

PMID: 38090385 PMC: 10686185. DOI: 10.1002/cai2.92.

References

Wagner L, Burger R, Guichard S, Raimondi S, Santana V, Furman W . Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR. J Pediatr Hematol Oncol. 2006; 28(10):635-41. DOI: 10.1097/01.mph.0000212976.13749.8a. View

Thomson B, Hawkins D, Felgenhauer J, Radich J . RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma. Bone Marrow Transplant. 1999; 24(5):527-33. DOI: 10.1038/sj.bmt.1701939. View

Cheung I, Feng Y, Gerald W, Cheung N . Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res. 2008; 14(21):7020-7. PMC: 2670609. DOI: 10.1158/1078-0432.CCR-08-0541. View

Trager C, Vernby A, Kullman A, Ora I, Kogner P, Kagedal B . mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. Int J Cancer. 2008; 123(12):2849-55. DOI: 10.1002/ijc.23846. View

de Alava E, Lozano M, Patino A, Sierrasesumaga L, Pardo-Mindan F . Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples. Diagn Mol Pathol. 1998; 7(3):152-7. DOI: 10.1097/00019606-199806000-00005. View

Mehes G, Luegmayr A, Hattinger C, Lorch T, Ambros I, Gadner H . Automatic detection and genetic profiling of disseminated neuroblastoma cells. Med Pediatr Oncol. 2001; 36(1):205-9. DOI: 10.1002/1096-911X(20010101)36:1<205::AID-MPO1050>3.0.CO;2-G. View

Cheung I, Barber D, Cheung N . Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res. 1998; 4(11):2801-5. View

Cheung I, Feng Y, Vickers A, Gerald W, Cheung N . Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. J Mol Diagn. 2007; 9(2):237-41. PMC: 1867438. DOI: 10.2353/jmoldx.2007.060130. View

Grau E, Oltra S, Martinez F, Orellana C, Canete A, Fernandez J . MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors. J Cancer Res Clin Oncol. 2008; 135(4):523-31. DOI: 10.1007/s00432-008-0484-1. View

10.

Cheung I, Sahota A, Cheung N . Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis. Cancer. 2004; 101(10):2303-8. DOI: 10.1002/cncr.20660. View

11.

Beck D, Maritaz O, Gross N, Favrot M, Vultier N, Bailly C . Immunocytochemical detection of neuroblastoma cells infiltrating clinical bone marrow samples. Eur J Pediatr. 1988; 147(6):609-12. DOI: 10.1007/BF00442474. View

12.

Corrias M, Haupt R, Carlini B, Parodi S, Rivabella L, Garaventa A . Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients. Clin Cancer Res. 2006; 12(19):5680-5. DOI: 10.1158/1078-0432.CCR-06-0740. View

13.

Beillard E, Pallisgaard N, van der Velden V, Bi W, Dee R, van der Schoot E . Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia. 2003; 17(12):2474-86. DOI: 10.1038/sj.leu.2403136. View

14.

Trager C, Kogner P, Lindskog M, Ponthan F, Kullman A, Kagedal B . Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem. 2003; 49(1):104-12. DOI: 10.1373/49.1.104. View

15.

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

16.

Ladisch S, Wu Z, Feig S, Ulsh L, Schwartz E, Floutsis G . Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer. 1987; 39(1):73-6. DOI: 10.1002/ijc.2910390113. View

17.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

18.

Athale U, Shurtleff S, Jenkins J, Poquette C, Tan M, Downing J . Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol. 2001; 23(2):99-104. DOI: 10.1097/00043426-200102000-00006. View

19.

Zoubek A, Ladenstein R, Windhager R, Amann G, Fischmeister G, Kager L . Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. Int J Cancer. 1998; 79(1):56-60. DOI: 10.1002/(sici)1097-0215(19980220)79:1<56::aid-ijc11>3.0.co;2-f. View

20.

Moss T, Reynolds C, Sather H, Romansky S, Hammond G, Seeger R . Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med. 1991; 324(4):219-26. DOI: 10.1056/NEJM199101243240403. View